Le Lézard
Classified in: Health
Subjects: MAV, PSF, CFG

/R E P E A T -- Notice to the Media - The Chief Public Health Officer and the Deputy Chief Public Health Officer to hold a media availability on the novel coronavirus/

OTTAWA, Feb. 14, 2020 /CNW/ - The  Chief Public Health Officer, Dr. Theresa Tam, and the Deputy Chief Public Health Officer, Dr. Howard Njoo, will hold a media availability to provide an update on the novel coronavirus (referred to as COVID-19).

The officials will be available to answer questions from the media following their remarks.

February 15, 2020

12:00 PM (EST)

Teleconference Only
Toll-free (Canada/US) dial-in number:
Passcode: 6879820#

SOURCE Public Health Agency of Canada

These press releases may also interest you

at 07:00
Today, the Association of Black Cardiologists (ABC), Inc., is excited to kick off the official Heart Valve Disease (HVD) Awareness Day activities with a public community educational health event hosted by the Alliance for Aging Research and The...

at 03:00
Although many people thrive on praise, not everyone welcomes it. Modesty aside, a study conducted by Queendom.com reveals that some people who dismiss compliments struggle with their sense of self-worth, are more pessimistic, and are less happy....

21 fév 2020
Zhongchao Inc. ("Zhongchao" or the "Company") , a provider of healthcare information, professional training and educational services to healthcare professionals and the public in China, today announced the pricing of its initial public offering of...

21 fév 2020
Fresh Sprout International is recalling Fresh Sprouts brand Fresh Bean Sprouts from the marketplace due to possible Salmonella contamination. Consumers should not consume the recalled product described below. The following product has been sold in...

21 fév 2020
The U.S. Food and Drug Administration (FDA) has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple...

21 fév 2020
Lundbeck today announced that VYEPTItm (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults and will be available in April 2020. The recommended dose is 100 mg every 3...

News published on 15 february 2020 at 06:00 and distributed by: